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                                 INTRODUCTION 
 
An unusually high prevalence of glycosuria in non-diabetic patients who have 
acute myocardial infarction was noted as early as 1931. Stress hyperglycemia 
after MI is associated with an increased risk of in hospital mortality in patients 
with & without diabetes. More over  a positive association between 
hyperglycemia at the time of the event and subsequent mortality from MI has 
been reported. 
The factors of hyperglycemia in acute MI patients without previously noted  
abnormal glucose homeostasis are different. Transitory hyperglycemia and 
glycosuria are common during the acute stage of MI and usually explained as a 
manifestation of stress. 
Acute MI  has an extremely unfavourable effect on glucose metabolism. In such 
situations there is very often an increase in catecholamine concentration 
suppression  of insulin release , development of peripheral insulin resistance 
and increase in growth hormone and cortisol concentrations. 
A decreased secretion of insulin can be dangerous. During ischemia the 
passage of glucose into cells become critical, since the heart switches from 
aerobic metabolism with primary utilization of  fatty acids to anaerobic 
metabolism that depends on glucose as energy source. Insulin facilitates 
glucose uptake, whereas ketones, FFA and their oxidation products that 
develop during insulin deficiency inhibit its transfer across the cell membrane. 
The resulting hormonal & physiological changes during acute MI is intolerance 
which in such cases is usual even in non-diabetics. 
 
               In the present report an attempt has been made to predict blood sugar 
response in acute myocardial infarction and correlate with selected parameters. 
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                                     AIM OF THE STUDY 
 
 
 
 
 
1. To find out the prevalence of hyperglycemia on acute myocardial infarction in 
non-diabetic population. 
 
2. To identify the selected risk factors and correlate with blood sugar response. 
 
3. To correlate blood sugar level within hospital outcome. 
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                              REVIEW OF LITERATURE         
INTRODUCTION 
                      Historically metabolic response to injury was first noticed by John Hunter 
in 1794 .The literature is rich in conditions where stress hyperglycemia has been 
observed. The etiology can be physical , mental, psychological or physiological but all 
these factors share one common determinant i.e., stress resulting in a sequence of 
events culminating as hyperglycemia. 
  ETIOLOGICAL FACTORS 
                 Stress hyperglycemia has been observed in such trivial conditions like 
simple visit to a physician’s office(white coat hypertension).The range of stressful 
condition varies from mild to severe stress like myocardial infarction 
cerebrovascular accident, physical trauma, crush syndrome, hemorrhagic 
hypovolemia and shock. 
 
          Stress hyperglycemia has been documented in cancer patients . Psychological 
stress also leads to insulin resistance, raising blood glucose level .Sustained 
hyperglycemia was observed in rats subjected to hyper G stress  or swimming 
.Electroconvulsive therapy in psychiatric patients is a stressful event leading to 
hyperglucagonemia, suppression of insulin and a sustained rise in glucose 
concentration. Hyperglycemia  is  also observed during exercise in hot weather , 
emotional stress associated  with solitary confinement and environmental novelty.
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Glycemia was noticed with drug therapy and certain toxicological state. The 
anti-hypertensive drug sodium nitroprusside induced hypotension is a powerful 
stress producing factor leading to glucose intolerance.Overdosage or poisoning 
of verapamil , a calcium antagonist,causes peripheral insulin resistance leading 
to sustained elevation of blood glucose. Hyperglycemia has been observed in 
response to anaesthetic agents thiopental, propofol and diazoxide. It has also 
been seen in severe carbon monoxide poisoning due to stress of cerebral 
damage. Similarly L-dopa therapy , atropine injection , severe dehydration 
hypoxia and water intoxication are also associated with glucose intolerance. 
              The neurotoxin fraction of Egyptian cobra venom (Naja Naja) stimulates 
glucocorticoid release from adrenocortical cells. This lead to increased 
gluconeogenesis and inhibition of glucose utilization by the peripheral tissues, 
thus maintainig hyperglycemia during the period of stress.Stress hyperglycemia 
has been noticed in pediatric practice also. The pediatric emergencies are 
frequently associated with raised blood glucose level, where its magnitude is 
directly related to the severity of the illness. Stress hyperglycemia is seen in 
severely stressed premature infants on parenteral nutrition due to increased 
peripheral insulin resistance. Acute respiratory distress syndrome in children is 
one example associated with markedly raised blood glucose levels. Moreover 
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,hyperglycemia has been observed in 5.5% of all critically ill infants ,when they 
are infused with 10%dextrose solution. 
 
Diarrhoea is frequently noticed in day-to-day practice. Interestingly 
hyperglycemia is a recognised complication of diarrhoea associated with 
hemolytic uremic syndrome and high mortality. The hyperglycemia in diarrhoeal  
states is a stress response to severe dehydration and hypovolemia. 
PATHOPHYSIOLOGY 
                           Carbohydrates serve as major fuel for the tissues of mammals 
except ruminant and universal fuels for fetus , metabolized as first line 
substrate for energy production. In health ,blood glucose level is maintained in 
a narrow range by a complex interplay of many counterbalancing processes. 
The factors which tend to raise the blood  glucose level ,include diet, 
glycogenolysis  and gluconeogenesis. 
                     Liver and muscles are the organs where glycogen is brokendown. 
However, liver glycogen yields glucose in  the blood , as the first line fuel, if  the 
need arises e.g.,during fasting. Gluconeogenesis from noncarbohydrate 
sources like lactate , glycerol, alanine and propianate takes place in the liver 
and kidneys ,as these organs contains all enzymes involved in the 
gluconeogenic pathway. 
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Glucose is removed from the blood principally by five pathways : 
(i) uptake and  subsequent glcolysis of glucose by kreb’s cycle in all 
cells of the body 
(ii) stored in the liver and muscles as glycogen by glycogenesis, 
(ii) excess is converted via glycerol-3-phosphate pathway to acylglycerol 
in the adipose tissues i.e.,lipogenesis, 
(iii) remaining excess is converted into non essential amino acids, 
(iv) loss in the urine ,which is normally an insignificant route of glucose 
removal in health. 
 
             During stress states catecholamines and a number of other 
hormones contribute to the development of hyperglycemia by directly 
stimulating glycogenolysis in the liver . In normal circumstances 
hyperglycemia stimulates the secretion  of insulin and inhibits the secretion 
of glucagon . Insulin in turn tends to lower the blood glucose through its 
uptake by the liver and adipose tissue. 
 
         In stress , the key role of catecholamines  is to interfere with insulin 
mediated glucose uptake by peripheral tissues and  at the same time to 
inhibit the glucose –induced stimulation of insulin released by  the pancreas. 
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          The ability of catecholamines to interfere with each component of the 
glucoregulatory response i.e., stimulation of splanchnic  and peripheral 
glucose uptake and suppression of hepatic glucose production, accounts for 
sustained hyperglycemia and  makes catecholamines an important 
contributor to stress induced hyperglycemia. The diabetics ,when exposed 
to surgical stress ,demonstrate greater degree of hyperglycemia than normal 
people due to decreased metabolic clearance rate of glucose because of 
insulin deficiency and /or increased peripheral resistance .On the other hand   
the counter regulatory response to hypoglycemic stress in diabetics is 
abolished due to increased somatostatin: glucagon ratio in their pancreas 
with the result that there is no catecholamine –mediated raise in their blood 
glucose levels .Thus ,hypoglycemic stress can be life threatening in diabetic 
patients. Cytokines like interleukin -1 produced endogenously within the 
brain represent an important compenent of central regulation of metabolic 
response to stress as intra –cerebroventricular injection of this cytokine 
produces hyperglycemia and sustained elevation  of glucagons and 
corticosterone. 
DIFFERENTIAL DIAGNOSIS 
                               Having learned about stress hyperglycemia and its cause 
along with its consequence ,it has to be distinguished from underlying true 
diabetic status by the following means . 
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a) by measuring islet antibodies ,insulin antibodies and stimulated insulin 
release especially in children 
b) by measuring fructosamine, 
c)  by measuring glycosylated haemoglobin in blood 
 
 
CLINICAL FORMS OF STRESS HYPERGLYCEMIA 
CARDIOVASCULAR DISEASE AND CENTRAL NERVOUS SYSTEM  
                      Patients with cardiovascular disease commonly  have a type of 
stress hyperglycemia  during the acute phase of myocardial infarction or stroke 
or during  any prolonged hypotensive response related to impaired cardiac 
performance or bleeding episode , altered carbohydrate metabolism is likely. At 
the onset of an acute myocardial infarction  and acute stroke , there is an 
immediate increase of  plasma catecholamines followed by increase of  the 
other counter regulatory hormones , such as glucagon , cortisol and growth 
hormone . Impaired insulin secretion is prominent in these patients . In addition 
to the release of catecholamines  from central sympathetic stimulation , there is 
some evidence that local damage to cardiovascular neurons may be a source of 
circulating catecholamines during infarction. This may explain the relationship 
between the degree of hyperglycemia and the eventual prognosis of acute 
cardiovascular  and  CNS events. Peripheral vascular occlusive disease 
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probably activates the system by stimulation of pain fibers , whereas 
cerebrovascular occlusive disease or cerebral hemorrhage may produce 
activation of central neurons by a local hypoxic stimulus. since adrenergic 
system is fully active and the metabolic effects are quite different from those 
seen in systemic hypoxia . 
              Since diabetics often have myocardial infarction and /or chronic 
cardiovascular  disease and  stroke, the pathophysiology of non insulin 
dependent diabetes and pathophysiology of neuroendocrine related sress 
hyperglcemia  may infact  not be different. Therefore hyperglycemia should not 
be ascribed to non insulin dependent diabetes during any acute cardiovascular 
event.    
PAIN AND TRAUMA 
 Hyperglycemia and impaired glucose tolerance are common during 
any kind of traumatic injury. The mechanism of the stimulus to the autonomic 
nervous system and the activation of the stress response appears to be the pain 
associated with trauma. The major effect is to produce a hypercatabolic state 
characterized by high glucose levels, impaired insulin secretion, increased 
gluconeogenesis, increased muscle proteolysis and increased mobilization of 
fatty acids from adipose tissue . It would appear that reduction of 
catecholamines and increased insulin secretion are the two major goals to be 
achieved. 
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SURGERY AND ANAESTHESIA  
Understanding the contribution of sympathetic activation to the metabolic 
response to surgical trauma is complicated by the effects of anaesthetic agents 
themselves on the sympathetic nervous system. The depth of anaesthesia is 
also an important factor .Decreased parasympathetic activity and activation of 
pituitary hormones promote hyperglycemia. 
BURNS 
Major burns are associated with  a hypercatabolic state, that includes 
elevations of cortisol, growth hormone and glucagon, as well as impaired 
insulin secretion due to activation of sympathetic neurons and epinephrine 
release. Since this burn injury is often associated with sepsis,it is possible that 
leukocyte endogenous mediators may be playing a role. It is possible that the 
massive reabsorption of tissue and increased levels of plasma aminoacids are 
used as a source for gluconeogenesis and may be important to this continued 
heat production. 
SEPSIS 
Carbohydrate metabolism is often altered by sepsis. Usually 
carbohydrate intolerance and increased levels of counter-regulatory hormones 
like glucagon , cortisol and growth hormone have been reported. Mechanisms 
for the increased secretion of these hormones during uncomplicated infections 
are not certain, but it has been suggested that they may be related to the 
production of endotoxin like substances from the leukocytes. These 
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substances,which may be related or identical to the interleukins, may explain 
both the pyrogenic and metabolic responses  to bacterial sepsis. These 
leukocytes has been shown to increase glucagon secretion to raise plasma 
glucose. 
HYPOXIA 
              Sudden reduction of oxygen tension due to any cause is a potent 
stimulant of sympathetic nervous system activity. Hypertension is common due 
to sympathetic vasoconstriction .The explanation for  this paradox appears to 
lie in two factors :(1)there may be simultaneous activation of the vagus and 
(2)severe hypoxia appears to impair the ability of beta adrenergic receptors to 
respond. 
HYPOTHERMIA AND COLD STRESS 
                   Cold stress and hypothermia are both associated with severe 
carbohydrate intolerance. In cold,  stress metabolism increases as a result of 
activation of sympathetic nervous system and by shivering. In hypothermia, 
shivering is usually suppressed , thus reducing metabolic heat production and 
leading to lowered body temperature .Therefore the two physiologic states, 
although related , are quite different because of the vastly different responses to 
cold exposure. Therefore , during cold exposure with shivering there may be no 
increase of plasma glucose levels  even though glucose turnover is markedly 
increased. 
 
 19
HYPOGLYCEMIA 
       Hypoglycemia elicits a sympatho adrenal response; a vagally mediated 
parasympathetic response that activates the hypothalamo –pituitary 
system.While hyperglucagonemia during hypoglycemia can be modulated by 
adrenergic and cholinergic blockade in experimental animals , this has  been 
difficult to show in intact human beings . In man ,recovery from hypoglycemia is 
usually normal in the absence of either a catecholamine or a glucagon 
response, but if both are missing. Thus attempts to block glucagon release lead 
to little impairment of counter-regulation of insulin induced hypoglycemia and 
attempts to block the effects of autonomic nervous stimulation by atropine and 
/or adrenergic blockade also produces impairment of recovery mechanism from 
insulin induced hypoglycemia. 
STRESS HYPERGLYCEMIA IN DIABETES MELLITUS 
INSULIN DEPENDENT DIABETES MELLITUS 
                  IDDM is chatacterised by an islet lesion leading to markedly impaired 
insulin secretion with eventual death and loss of almost all of the islet B cells. 
Elevated levels of catecholamines , cortisol , growth hormone and glucagon are 
characteristic of DKA. When the hyperglycemia becomes sufficient in 
magnitude to lead to glycosuria and elctrolyte loss , it is the subsequent volume 
depletion associated with glycosuria that activates the counter-regulatory 
hormones epinephrine , glucagon, growth hormone and cortisol to produce the 
 20
full blown diabetic ketoacidosis syndrome. The rationalisation was that 
catecholamine induced lipolysis could be prevented so that episodes of poor 
diabetes control would be associated with marked reduction of frequency of 
hospitalisation for  ketoacidosis, in contrast to other forms of therapy directed 
at reducing the environmental stress factors in these patient’s lives. A variety of 
stress states are associated with increased need for insulin in IDDM . It is also a 
commonly observed phenomenon that deterioration  of diabetes control is likely 
during episodes of sepsis , burns , hypoxia ,  hypotension or vascular accidents 
in insulin treated diabetes patients. 
NON- INSULIN DEPENDENT  DIABETES MELLITUS 
     Islet B cells  play a key role in any hyperglycemic state .Due  to the feedback 
nature of islet regulation , it appears that increased hepatic glucose production 
and /or decreased peripheral glucose utilization alone or together cannot lead to 
sustained hyperglycemia unless the islet fails to adapt .On theoretical grounds 
one would expect that hyperglycemia in non- insulin dependent diabetes  must 
be associated with an abnormality of islet function. Thus any stimulus that 
tends to impair insulin action or accelerate hepatic glucose production will be 
more effective in elevation of glucose in NIDDM patients because it would 
require a greater degree of hyperglycemia for islet cell adaptation to occur . It 
has now become apparent that islet B cells are more sensitive to the ability of 
epinephrine to impair islet responses to glucose, with their attendant effects on 
the sensitivity of islet B cells to non glucose stimulants. 
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             ACUTE MYOCARDIAL INFARCTION 
HISTORY 
                Although the clinical syndrome of angina was described in the 1770s, 
it was not until 1912 that James B. Herrick described acute MI . This delay is 
largely attributed to the prevailing view that a sudden coronary occlusion would 
be uniformly fatal and to the lack of understanding of the pathophysiology. Just 
before Herrick reported the MI syndrome, two Russian physicians, Obrastzow 
and Straschesko, published cases of acute coronary thrombosis and the 
differential diagnosis of acute MI versus angina in the German literature . In the 
landmark paper by Herrick, he wrote, “The clinical manifestations of coronary 
obstruction will evidently vary greatly  depending on the size, location and 
number of vessels occluded. The symptoms and end-result must also be 
influenced by blood pressure, by the condition of the myocardium not 
immediately affected by the obstruction, and by the ability of the remaining 
vessels to properly carry on their work, as determined by their health or 
disease”  
For nearly 70 years, however, there was a failure to meaningfully build on 
Herrick’s visionary paper. There was considerable reluctance to accept the 
notion that coronary thrombosis was the proximate cause. There were a few 
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isolated exceptions. Levine published a book on coronary thrombosis in 1929 
.Fletcher and associates administered intravenous streptokinase (SK) in 24 
patients with acute MI in 1958 and Boucek, using an aortic root injection, 
nonselectively administered fibrinolysin (SK and human plasmin) to eight 
patients after acute MI in 1960 . Later, in 1976, Chazov and a Russian team 
administered direct, intracoronary fibrinolysin to two patients, and the paper 
was published in Russian . Rentrop, in 1979, reported the use of intracoronary 
SK in five patients with evolving MI , and this ushered in the reperfusion era that 
initially used intracoronary SK in selected centers in the early 1980s. 
Nearly simultaneous to the development of a reperfusion therapy for MI was the 
other critical insight to its pathophysiologic underpinning. The classic 
angiographic study of DeWood and colleagues from Spokane , showing 
thrombotic occlusion in 87% of patients within 4 hours of symptom onset , 
provided the backbone for a revolutionary change to aggressive management of 
acute MI. This trial was powerful in convincing the medical community that 
coronary thrombus was indeed the proximate cause in nearly all acute MI 
patients. 
Incidence and Significance  
                         The true incidence of acute MI is unknown. Beyond the 
significant proportion of patients who die before reaching the hospital, 
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estimated at 200,000 to 300,000 patients in the United States per year , it is 
estimated that approximately 1 million patients present to a hospital each year 
with some type of MI as the principal diagnosis . Of these, we know that roughly 
200,000 patients receive reperfusion therapy in the United States per year, and 
that this represents only 20% to 30% of the patients who are assessed for 
eligibility for aggressive management . The breakdown of infarctions is also 
unclear, with a split between the classic ST-segment elevation and the non–ST-
segment elevation (also known as non–Q wave). The latter group is difficult to 
differentiate from unstable angina on presentation, but it is estimated that 
approximately one-half of patients present with either significant ST-segment 
elevation (greater than 1 mm) or fall into the latter category with abnormal ST-
segment depression or T-wave inversion. 
The incidence and mortality resulting from MI is on the decline. Not only has the 
fatality rate been reduced as better therapies have evolved , but the absolute 
number of MI events has continued to decrease since the 1970s. This is likely 
attributable to the many advances in preventive cardiology, including treatment 
of hypertension, avoidance of smoking, management of hypercholesterolemia, 
improved diet and exercise, and the use of prophylactic aspirin. It may also be 
an outgrowth of the high rates of surgical and percutaneous coronary 
revascularization in the United States, where the treatment of angina is more apt 
to be bypass surgery or angioplasty, rather than medical management. 
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Although prevention of MI is not a prominent effect of coronary 
revascularization, intervening early in the course of atherosclerotic coronary 
disease may change its natural history. The most pronounced effect on 
reducing the incidence of MI appears to have resulted from the use of HMG-CoA 
reductase inhibitors , which has led to the concept that acute MI may even be 
“extinct” someday . Clearly, the most important initiatives for the condition of 
MI are in its prevention, because once the process of plaque rupture is 
unleashed, it is much more difficult to interrupt. 
Pathophysiology  
                     Coronary atherosclerotic disease is the underlying substrate in 
nearly all patients with acute MI. The initiating event is a crack or fissure in the 
diseased arterial wall, which occurs as a result of loss of integrity of the plaque 
cap, which is the fibrous tissue overlying the plaque and partitioning the 
atheroma from the arterial lumen . The fissure or even frank plaque rupture 
leads to exposure of subendothelial matrix elements such as collagen, 
stimulating platelet activation, and thrombus formation. Furthermore, tissue 
factor is released with the arterial injury, which directly activates the extrinsic 
coagulation cascade and promotes the formation of fibrin . If an occlusive 
thrombus forms, patients may develop an acute ST-segment elevation MI unless 
the subtended myocardium is richly collateralized. On the other hand, the 
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thrombus formed may not be occlusive, but rather mural, and the patient may 
develop unstable angina or non–ST-segment elevation changes on the ECG (ST-
depression or T-wave changes), which denote the lack of a “current of injury” or 
full-thickness (subendocardial to epicardial) myocardial ischemia . 
                       Understanding the reasons why plaques crack may provide a 
better means of preventing acute MI, rather than intervening at the late phase 
after the event has been initiated. Plaques that rupture or fissure tend to have a 
thin fibrous cap, a high lipid content, few smooth muscle cells, and a high 
proportion of macrophages and monocytes . These mononuclear cells are 
conceived as a major trigger in plaque rupture by their release of such 
proteases as monocyte chemotactic protein (MCP-1) and matrix 
metalloproteinases (examples are collagenases, stromelysin, elastases), which 
chemically digest the plaque cap. Of note, the 3-hydroxy-3-methylglutaryl 
coenzyme A (HMG-CoA) reductase inhibitors have been shown to reduce the 
incidence of MI, and this is likely related to reduction in lipid content, as well as 
a favorable antiinflammatory effect on the cellular plaque constituents and 
chemokines . Loss of integrity of the arterial wall and platelet thrombus, with 
cessation of coronary blood flow through the infarct-related artery, thus drives 
myocardial ischemia and injury. As elegantly described by Reimer and 
Jennings, the wavefront of necrosis extends from the subendocardium to the 
subepicardium , and the extent of necrosis varies as a function of collateral 
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flow, the length of time that coronary blood flow has halted, and the extent of 
diminution of coronary blood flow. In many patients, there is a stuttering quality 
of MI with severe pain often denoting the cutoff of blood supply, and less chest 
pain, with partial, albeit insufficient, reflow. This dynamic quality of the infarct 
vessel blood flow pattern in acute MI (altered vasomotor tone or spasm) is likely 
related to the release of vasoactive amines from the activated platelets and loss 
of endothelial function. 
                          The thrombus that occludes the coronary artery is a mixture of 
white (platelet-rich) and red (fibrin- and erythrocyte-rich) clot. In some patients, 
there is a more dominant role of platelets, whereas in others predominantly 
fibrin-rich thrombus at the arterial injury site is found. Stagnation thrombosis 
results from the lack of blood flow through the infarct vessel, thus leading to 
calumniation of red thrombus proximal to the original occlusion site . There is 
rarely frank herniation of the plaque occluding the lumen, which is known as 
plaque disaster . 
                            On the other hand, the mural thrombus in patients without ST-
segment elevation MI is more apt to be platelet rich and not accompanied by 
stagnation as there is no sustained cutoff of coronary blood flow. Depending on 
the extent and duration of ischemia, the patient may not experience any 
myocardial necrosis (unstable angina) or develop myocardial damage (non–ST-
elevation or non–Q-wave infarction). Beyond what is occurring at the arterial 
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injury site and proximal to it, there is the potential for embolization of atheroma 
constituents or platelet thrombus distally. This is not typically found at 
postmortem but requires careful histologic inspection . When this occurs, a 
further explanation to cessation of myocardial blood flow is provided. 
                         Although there is considerable variability in time of presentation, 
the plaque fissure events are more likely to happen in the early morning hours, 
especially on awakening, owing to the circadian rhythm, with its temporal 
cyclic-enhanced platelet aggregation, and reduced fibrinolytic potential related 
to higher plasminogen activator inhibitor levels . Surges of epinephrine may 
also have a role, as evidenced by a considerably higher rate of MIs during Scud 
missile attacks in the Gulf War and during the Los Angeles earthquake . Beyond 
catecholamine excess, there are several factors that ultimately may precipitate 
plaque fissure, including infection or inflammation of the diseased coronary 
artery segment. 
 PATHOPHYSIOLOGY OF OTHER ORGAN SYSTEMS  
ENDOCRINE FUNCTION  
PANCREAS 
   Hyperglycemia and impaired glucose tolerance are common in patients with 
AMI. Although the absolute levels of blood insulin are often in the normal range, 
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they are usually inappropriately low for the level of blood sugar, and there may 
be relative insulin resistance as well. Stress-induced hyperglycemia in the 
setting of AMI is associated with an increased risk of mortality even in patients 
without diabetes mellitus. Patients with cardiogenic shock often demonstrate 
marked hyperglycemia and depressed levels of circulating insulin, often with 
complete suppression of insulin secretion in response to tolbutamide. These 
abnormalities in insulin secretion and the resultant impaired glucose tolerance 
appear to be secondary to a reduction in pancreatic blood flow as a 
consequence of splanchnic vasoconstriction accompanying severe LV failure. 
In addition, increased activity of the sympathetic nervous system with 
augmented circulating catecholamines inhibits insulin secretion and augments 
glycogenolysis, also contributing to the elevation of blood sugar.Glucose 
appears to be a more favorable energy source than free fatty acids for the 
ischemic myocardium by more efficiently replenishing the Krebs cycle and 
stimulating contractility .Because hypoxic heart muscle derives a considerable 
portion of its energy from the metabolism of glucose  and because insulin is 
essential for the uptake of glucose by the myocardium as well as for myocardial 
protein synthesis and inhibition of lysosomal activity, the deleterious effects of 
insulin deficiency are clear. These metabolic considerations, combined with 
epidemiological observations that diabetic patients have a markedly worse 
prognosis, have served as the foundation for efforts to more aggressively 
administer insulin-glucose infusions to diabetics with AMI.  
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ADRENAL MEDULLA 
                             Excessive secretion of catecholamines produces many of the 
characteristic signs and symptoms of AMI. The plasma and urinary 
catecholamine levels are highest during the first 24 hours after the onset of 
chest pain, with the greatest rise in plasma catecholamine secretion occurring 
during the first hour after the onset of MI. These high levels of circulating 
catecholamines in patients with AMI correlate with the occurrence of serious 
arrhythmias and result in an increase in myocardial oxygen consumption, both 
directly and indirectly, as a consequence of catecholamineinduced elevation of 
circulating free fatty acids. As might be anticipated, the concentration of 
circulating catecholamines correlates with the extent of myocardial damage and 
incidence of cardiogenic shock, as well as both early and late mortality rates.  
Circulating catecholamines enhance platelet aggregation; when this occurs in 
the coronary microcirculation, the release of the potent vasoconstrictor 
thromboxane A2 may further impair cardiac perfusion. The marked increase in 
sympathetic activity associated with AMI serves as the foundation for beta-
adrenoceptor blocker regimens in the acute phase.  
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ADRENAL CORTEX  
  Plasma and urinary 17-hydroxycorticosteroids and ketosteroids, as well as 
aldosterone, are also markedly elevated in patients with AMI. Their 
concentrations correlate directly with the peak level of serum creatine kinase, 
implying that the stress imposed by larger infarcts is associated with greater 
secretion of adrenal steroids. The magnitude of the elevation of cortisol 
correlates with infarct size and mortality. Glucocorticosteroids also contribute 
to the impairment of glucose tolerance.  
RENAL FUNCTION  Both prerenal azotemia and acute renal failure can 
complicate the marked reduction of cardiac output that occurs in cardiogenic 
shock. On the other hand, an increase in circulating atrial natriuretic peptide 
occurs after AMI, an increase that is correlated with the severity of left 
ventricular failure.  
DIAGNOSIS  Acute MI is a clinical syndrome for which a constellation of 
subjective and objective parameters need to be assessed. The diagnosis must 
be obtained rapidly and accurately, and misdiagnosis can have catastrophic 
sequelae. The individual components of making the diagnosis are discussed 
separately, but it is the integration of all of them that facilitates the accuracy and 
speed of the clinical syndrome recognition. 
 31
 
 
History  
                    The classic symptoms of MI are intense, oppressive, excruciating 
chest pressure, with an impending sense of doom and radiation of the pain to 
the left arm. However, the other symptoms of chest heaviness or burning, 
radiation to the jaw, neck, shoulder, back, or both arms may be encountered. 
Indigestion is common, especially with inferior wall MI. Nausea and vomiting, 
particularly the former, are typical. Profuse diaphoresis is also a frequent 
characteristic. Taken together, the patient with a clear-cut presentation is 
experiencing a unique, discrete, painful event that has induced fear. However, 
the subtleties of the history are more common and challenging. It is important 
to ask whether there were premonitory signs of chest discomfort (not 
necessarily pain) in the preceding week or two. Pain or discomfort may be 
completely localized to the arm or shoulder. Quite commonly, only the 
symptoms of indigestion and nausea prevail, such that the patient attributes the 
episode to heartburn and resorts to taking antacids. 
                   The identification of risk factors, such as smoking, known 
cholesterol elevation, diabetes, hypertension, and family history, is a supportive 
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piece that helps to put the acute history into context. The chest discomfort that 
causes the patient to seek medical attention is usually sustained (greater than 
20 minutes), but can be stuttering. 
                            Other accompanying symptoms include dyspnea, which is of 
concern because it may denote incipient congestive heart failure or, 
alternatively, is an outgrowth of the patient’s anxiety. Palpitations or syncope 
are unusual, but a history of lightheadedness or dizziness and presyncope often 
reflects the underlying vagotonia or bradyarrhythmias. When syncope, or an 
out-of-hospital arrest has occurred, there is a high likelihood of ventricular 
tachycardia as an explanation. 
 
              The differential diagnosis is quite broad (because many conditions can 
masquerade as acute MI) including aortic dissection, pericarditis, esophagitis, 
myocarditis, pneumonia, cholecystitis, and pancreatitis. Of these conditions, it 
is always worth considering that the patient has aortic dissection until proven 
otherwise, so that this diagnosis is not missed. Although considerably less 
common than acute MI, the therapies for the two conditions are entirely different 
and, for example, the use of fibrinolytic therapy for aortic dissection could be 
disastrous. 
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                   MOLECULAR MARKERS OF MYOCARDIAL INFARCTION              
MARKER  MW (D)  
RANGE OF 
TIMES TO 
INITIAL 
ELEVATION 
(hr)  
MEAN TIME TO PEAK 
ELEVATIONS 
(NONTHROMBOLYSIS) 
TIME TO 
RETURN 
TO 
NORMAL 
RANGE  
MOST 
COMMON 
SAMPLING 
SCHEDULE 
hFABP  14,000-15,000  1.5  5–10 hr  24 hr  
Adm &then 4 
hr later  
Myoglobin  17,800  1–4  6–7 hr  24 hr  Frequent; 1–2 hr after CP 
cTnI  23,500  3–12  24 hr  5–10 d  
Once at least 
12 hr after 
CP  
cTnT  33,000  3–12  12 hr–2 d  5–14 d  
Once at least 
12 hr after 
CP  
MB-CK  86,000  3–12  24 hr  48–72 hr  Every 12 hr × 3 
MM-CK 
tissue 
isoform  
86,000  1–6  12 hr  38 hr  60–90 min after CP  
MB-CK 
tissue 
isoform  
86,000  2–6  18 hr  Unknown  60–90 min after CP  
LD  135,000  10  24–48 hr  10–14 d  
Once at least 
24 hr after 
CP  
MHC  400,000  48  5–6 d  14 d  Once at least >2 d after CP 
hFABP = heart fatty acid binding proteins;; cTnI = cardiac troponin I; cTnT = cardiac 
troponin T; MB-CK = MB isoenzyme of creatinine kinase (CK); MM-CK = MM isoenzyme of 
CK; LD = lactate dehydrogenase; MHC = myosin heavy chain; CP = chest pain  
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ANGIOGRAPHY  
                           On occasion, even with all of the tools outlined, the diagnosis is 
uncertain. This may be the result of atypical symptoms and an ECG that is 
difficult to interpret. In a patient in whom reperfusion therapy is contemplated, 
an approach that can rapidly establish the diagnosis is emergency coronary 
angiography. By demonstrating an acutely occluded infarct vessel, with the 
characteristic appearance of thrombus or a cutoff sign at the point of occlusion, 
coupled with left ventriculography to ascertain the segmental wall motion 
profile, angiography can at times be helpful for a difficult diagnosis. Examples 
of patients who may present with ambiguity are those with an acute myocarditis 
with diffuse ECG changes, or patients with prior bypass surgery and previous 
MI, or those without a characteristic pattern on ECG. Furthermore, angiography 
can serve as the foundation for primary balloon angioplasty to achieve 
reperfusion. 
Treatment  
Analgesia and Supportive Measures  
                 The first step in treating the patient, while more definitive therapy is 
being prepared (such as fibrinolytics or transfer to a cardiac catheterization 
laboratory), is to make the patient comfortable via supplemental oxygen (usually 
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nasal cannula at 2 L per minute) and morphine (2 to 4 mg intravenously and 
repeat as necessary). Before using morphine, it is helpful to have quickly tried 
sublingual nitroglycerin to determine whether there is a reversible component 
of the ischemia, pain, and ECG changes. Furthermore, if the patient is Killip 
class I or II and has no bradycardia or hypotension (systolic pressure less than 
110 mm Hg), then use of intravenous beta-blockade can be considered as a 
means of reducing the extent of ischemia and lessening the need for narcotic 
analgesia. 
Aspirin  
                           The use of aspirin is a cornerstone of therapy for patients with 
acute coronary syndromes. It should be initiated as quickly as possible when 
the diagnosis is made, at a dose of 160 mg by chewable administration (2 80 
mg “baby” aspirin) or a 325-mg orally administered tablet. No enteric coated 
formulation of aspirin should be used. The validation for the importance of 
aspirin in this setting is derived from the landmark International Studies of 
Infarct Survival (ISIS-2) trial , which showed it is lifesaving . Since this trial, 
aspirin has been used in all patients with acute MI, and other trials have 
provided strong evidence for its use in unstable angina and non–ST-elevation 
MI . The dose that has been routinely recommended is 325 mg per day, and it is 
continued indefinitely. 
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Clopidogrel  
                 The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial 
assessed the combination of aspirin plus clopidogrel compared with aspirin in 
patients without ST-segment elevation MI. With a 20% reduction of ischemic 
events, particularly MI (or reinfarction), there are supportive data to use this 
second antiplatelet . 
Beta-Blockade  
                  Nearly all of the data available for the use of beta-blockers in acute MI 
are derived from the prereperfusion era. There is extensive support for the 
usefulness of beta-blockade to reduce recurrent ischemia and arrhythmias and 
improve survival . The largest trial of intravenous beta-blockade, ISIS-1, 
suggested that the predominant benefit was mediated via the reduction of 
cardiac rupture events . Only two placebo-controlled trials in the contemporary 
era of reperfusion therapy have been conducted, and one of these showed 
reduction in recurrent ischemia with the use of early intravenous followed by 
oral metoprolol . The trial was relatively small, however, and the primary end 
point of preserving cardiac function was not significantly affected. Likewise, a 
trial of intravenous metoprolol conducted by Van de Werf et al. was negative . In 
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the GUSTO-I trial, the use of intravenous beta-blockade was associated with an 
adverse profile of clinical outcomes including worse mortality and congestive 
heart failure . In this trial, the use of intravenous beta-blockade in 44% of 
patients was higher than many other large-scale thrombolytic studies, and it 
remains possible that the ill effects were related to administering therapy to 
patients with a large infarction or with marginal left ventricular function . 
Current recommendations are to use beta-blockers orally in patients with a 
preserved left ventricular ejection fraction (estimated at >40%), and to initiate 
this on the first or second day after presentation. Intravenous beta-blockade is 
particularly useful in patients who are hyperdynamic and hyperadrenergic, 
representing the unusual subset of relatively young patients who have 
tachycardia and hypertension disproportionate to the smallness of their MI 
territory. But the potential for reducing intracerebral hemorrhage, as 
demonstrated in the TIMI-2 trial, has not been confirmed in subsequent large-
scale efforts . 
Angiotensin-Converting Enzyme Inhibitors  
                             One of the most important advances in cardiovascular 
medicine in the last decade has been the demonstration of survival benefit for 
angiotensin-converting enzyme (ACE) inhibitors in patients with left ventricular 
dysfunction. In several trials of acute MI  various ACE inhibitors have been 
tested and shown, in aggregate, to promote survival, reduce the incidence of 
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heart failure, and, in selected trials, reduce the incidence of reinfarction and the 
need for revascularization. ACE inhibitors can be recommended in the first 24 
hours of an anterior MI (proximal or mid-LAD) or an MI complicated by either 
heart failure or ejection fraction less than 40%, or both. A graded dose schedule 
is used to avoid hypotension, especially with the first dose, with initiation of 
therapy on the first hospital day once the blood pressure is stabilized. 
Management of Lipids  
With the marked salutary effects on long-term survival, prevention of 
reinfarction, and subsequent coronary revascularization of HMG-CoA reductase 
drugs , it is important that a cholesterol panel (total, low-density lipoprotein, 
high-density lipoprotein) be obtained on admission and no later than the first 24 
hours 
 Thrombolytics or Primary Mechanical Reperfusion  
                      All patients with ST-segment elevation MI who present within 12 
hours from the onset of symptoms should be considered for myocardial 
reperfusion therapy . The list of absolute and relative contraindications is 
provided in the table. 
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 Contraindications and cautions for fibrinolytic use in myocardial infarction  
Contraindications 
Previous hemorrhagic stroke at any time; other strokes or cerebrovascular 
events within 1 yr 
Known intracranial neoplasm 
Active internal bleeding (does not include menses) 
Suspected aortic dissection 
Relative contraindications 
Severe uncontrolled hypertension on presentation (blood pressure >180/110 mm 
Hg) or chronic history of severe hypertension 
History of prior cerebrovascular accident or known intracerebral pathology not 
covered in contraindications 
Current use of anticoagulants in therapeutic doses (international normalized ratio 
2–3); known bleeding diathesis 
Recent trauma (within 2–4 wk), including head trauma or traumatic or prolonged 
(>10 min) cardiopulmonary resuscitation or major surgery (<3 wk) 
Noncompressible vascular punctures 
Recent (within 2–4 wk) internal bleeding 
For streptokinase/anistreplase: prior exposure (especially within 5 d–2 yr) or 
prior allergic reaction 
Pregnancy 
Active peptic ulcer 
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 Acute MI is a clinical syndrome for which a constellation of subjective 
and objective parameters need to be assessed. The diagnosis must be obtained 
rapidly and accurately, and misdiagnosis can have catastrophic sequelae. The 
individual components of making the diagnosis are discussed separately, but it 
is the integration of all of them that facilitates the accuracy and speed of the 
clinical syndrome recognition. 
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                                                RELATED STUDIES 
1. Admission blood glucose level as risk indicator of death after myocardial 
infarction in patients with and without diabetes mellitus. ( Archives of 
internal medicine 2004;164:982-988).                                                                         
                 In this study 737 non-diabetics were analysed. Of them 101 had 
admission blood glucose levels around 200 mgs% and mortality in these 
patients was comparable to that in patients who had established diabetes. 
 
    2.   Is blood glucose an independent predictor of mortality in acute myocardial l                         
infarction in the thrombolytic era. (JOURNAL OF THE AMERICAN COLLEGE 
OF CARDIOLOGY-vol 40,no.10 2002). 
               In this review it was concluded that hyperglcemia in acute MI was 
associated with poor outcome even among patients without known diabetes. 
 
   3.  Effects of stress hyperglycemia on acute myocardial infarction.(DIABETES 
CARE  vol.26.no. 11,november 2003).    
            During MI ,hyperglycemia is associated with increased levels of 
inflammatory markers ,enhanced expression of cytotoxic T-cells,which are 
implicated in limiting immune process. An increased  inflammatory immune 
response seems a likely mechanism linking acute hyperglycemia to poor 
outcome in MI patients. 
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4. Stress hyperglycemia and increased risk of death after MI in patients with 
and without diabetes ; a systematic review .(THE LANCET vol 355 , march 
4,2000).  
 In this review 14 articles describing 15 studies were identified . patients 
without diabetes who has blood glucose concentrations ≥range 6.1 -8 
mmol/L had a 3.9 fold higher risk of death more than patients without 
diabetes who had lower glucose concentration. 
 
5. Hyperglycemia and acute MI in a non-diabetic population.(DIABETOLOGIA 
CROATICA 32-4 ,2003). 
         The study was done in 412 non-diabetic patients. During their hospital 
stay   ,hyperglycemia was found in 27.43 % patients wihtout previously 
confirmed diabetes and had normalised in 90.27% of these patients by 
discharge.  
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                                    MATERIALS AND METHODS 
 
 
 
Place of study                               Department of Medicine 
                                                      
                                                        TMCH,Thanjavur. 
 
 
Type of study                                Prospective study. 
 
 
Period of study                             August 2005 – July 2006. 
 
 
Ethical Committee 
            Approval                          The present project was approved by                                             
                                                    
                                                      the ethical committee. 
 
 
Collaborating Department Department of Cardiology 
 & 
 Department of Diabetology. 
 
Consent                                       Informed consent was obtained from the     
  
                                                      Participants. 
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CASE SELECTION 
 
INCLUSION CRITERIA 
1.  All patients admitted with acute onset of ST elevation Myocardial infarction. 
2.  Those admitted within 12 hours after the onset of Myocardial infarction.  
EXCLUSION CRITERIA 
1. Known diabetic, hypertensive or cardio-respiratory illness. 
2. Patients on steroids, catecholamines . 
3. Those with pancreatitis,acute surgical conditions,hypovolemia&any  physical,                         
    Physiological or psychological stress. 
4. Those treated outside before admission. 
5. Those admitted 12 hours after the onset of Myocardial Infarction. 
6. Those suffered from Myocardial Infarction earlier. 
7. Those with metabolic disorders like acute/ chronic renal failure, hepatic     
   failure,etc. 
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MATERIALS  AND METHODS 
        A total of 50 consecutive patients admitted at TMCH,Thanjavur,with acute 
onset of ST elevation MI who satisfied the above criteria.Among these 10 non-
diabetic euglycemic patients as a control for the purpose of analysis . 
 
LIMITATIONS 
1. Small number of patients. 
2. Other risk factors were not elicited. 
3. Insulin level was not measured. 
 
SAMPLE COLLECTION 
1. Ethyl oxide sterilized syringe was used for collecting blood samples. 
2. Containers for collecting blood samples were marked, washed with                              
 distilled water & dried before collecting blood samples. 
3. Blood sugar taken at the time of admission &fasting blood sugar  
 Taken at 24 hrs, 48 hrs & 72 hrs respectively. 
 
ECG 
12 lead ECG was taken following standard methods. 
 
ECHO 
Echocardiogram was taken following standard methods. 
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BLOOD PRESSURE 
Blood pressure taken on the day of admission & everyday during hospital 
stay. Patients with systolic BP>140 mm Hg & diastolic BP>90 mm Hg,were taken 
as hypertensives. 
 
 
Criteria for diagnosing stress hyperglycemia 
1.    Blood sugar value of >150 mgs% at the time of admission. 
2.    Euglycemic  fasting  blood sugar  level on the next  subsequent days. 
 
CATEGORIES 
Based on the blood sugar values patients were categorized into 3 groups. 
GROUP  I        Hyperglycemic non-diabetics.(cases) 
                                                                                                                                  
GROUP  II        Hyperglycemic diabetics.(newly diagnosed) 
 
GROUP  III Euglycemic  non-diabetics.(control) 
 
STATISTICS 
             
                     Significance was considered if the ‘p’ value is <0.05. For selected  
 
variables correletation studies were made. 
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                                                    PROFORMA 
 
NAME:      AGE:   YRS  SEX:M/F  
OCCUPATION:     I.P. NO: 
ADDRESS:      D.O.A: 
       D.O.D: 
 
SYMPTOMS AT THE TIME OF ADMISSION: 
 CHEST PAIN  /      DYSPNOEA /     SWEATING   /      PALPITATIONS 
 GIDDINESS    /      OLIGURIA  /       PAIN & SWELLING IN JOINTS 
 
PAST HISTORY: 
  HYPERTENSION/   DIABETES MELLITUS  /    CHRONIC ALCOHOLISM/ 
  IHD/    DYSLIPIDEMIA/  DRUG INTAKE 
 
ECG: 
 
KILLIP’S CLASSIFICATION:  I / II / III / IV 
 
THROMBOLYSED  :                                               NOT THROMBOLYSED  :   
 
INVESTIGATIONS: 
a. Hb % :    b.  TC  :   c. DC  : 
d.   URINE   Â    ALB:    SUGAR:  DEPOSITS: 
e.   BLOOD SUGAR:                             f:  BLOOD UREA: 
g. SERUM CREATININE: 
 SERUM ELECTROLYTES:         Na+:                                         K+: 
 
i.  ECHOCARDIOGRAM : 
 
 
Sl. 
No. 
 
 
VARIABLES 
 
ON 
ADMISSION 
          
 
DAY 
2 
 
 
DAY 
3 
 
ON 
DISCHARGE 
 
 
 
1 
 
BLOOD SUGAR (mg%) 
 
 
(RANDOM) 
 
 
(FASTING) 
 
 
(FASTING) 
 
 
(FASTING) 
 
2 
 
ARRYTHMIAS 
 
    
 
3. 
 
CARDIOGENIC SHOCK 
 
    
 
4. 
 
DEATH 
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                                          OBSERVATION 
 
 
 
 
In the present study there were 39 males and 11 females out of 50 patients. 
 
20 patients where under Group I with stress hyperglycemia & normal fasting  
 
blood glucose levels, 20 patients were under Group II with hyperglycemia &  
 
newly detected diabetes mellitus and 10 patients were under Group III with  
 
euglycemia and Non diabetics.  
 
 
 
Distribution of patients according to group and sex   
 
 
 
 
 
GROUP 
 
NUMBER OF CASES  
 
MALE  
 
FEMALE 
 
PERCENTAGE 
     
    I 
 
20 
 
  15 
 
       5 
 
40% 
 
    II 
 
20 
 
  15 
 
      5 
 
           40% 
 
 
    III 
 
10 
 
   9 
 
      1 
 
           20% 
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                                           GENDER DISTRIBUTION 
 
 
 
   
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No significant correlation from each other .The age of the patients studied   
 
ranged from 32 yrs to 70 yrs. The mean age of patients with Group I , Group II  
 
and  Group III were 56 ± 14 , 57 ± 13 ,52 ± 13.5 years respectively. 
78%
22%
MALES
FEMALES
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                                             BLOOD SUGAR  
                                                            GROUP   I  
 
  
NUMBER OF DAYS RANGE (mg%) MEAN (mg%)   S.D     
 
ON ADMISSION 
    (RANDOM) 
 
      152-218 
 
168.6 
 
   18 
 
       DAY 2 
   (FASTING) 
 
 
       98-140 
 
 
 
116.5 
 
    10.5 
 
      DAY 3 
   (FASTING) 
 
 
      100-116 
 
 
106 
 
     5.3 
 
 ON DISCHARGE 
     (FASTING) 
 
 
      94-110 
 
101.3 
 
     5.7 
  
 
0
50
100
150
200
BLOOD 
SUGAR
ADM DAY 2 DAY 3 DIS
mgs%
BLOOD SUGAR RANGE FOR GROUP I
MEAN
S.D
 
Under Group I  blood sugar level at the of admission were in the range of 152-  
218 mgs% with a mean of 168.6 mgs%. 
A reduction in the blood sugar was noticed on subsequent days and it was 
statistically significant (p value < 0.001). 
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                                                 GROUP II 
 
 
NUMBER OF DAYS RANGE (mg%) MEAN (mg%)   S.D    
 
ON ADMISSION 
    (RANDOM) 
 
154-272 
 
201.85 
 
 34.4 
 
       DAY 2 
   (FASTING) 
 
 
108-286 
 
167.65 
 
49.05 
 
      DAY 3 
   (FASTING) 
 
 
 
108-276 
 
 
165.95 
 
 
43.5 
 
 ON DISCHARGE 
     (FASTING) 
 
 
132-218 
 
170.23 
 
26.73 
 
0
50
100
150
200
250
BLOOD 
SUGAR
ADM DAY 2 DAY 3 DIS
mgs%
BLOOD SUGAR RANGE FOR GROUP II
MEAN
S.D
 
 
In this category , there is persistent elevation  of fasting  blood sugar level  in 
the subsequent days. 
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                                                 GROUP III    
 
 
 
 
NUMBER OF DAYS RANGE (mg%) MEAN (mg%)   S.D    
 
ON ADMISSION 
    (RANDOM) 
 
68-124 
 
101.6 
 
19.9 
 
       DAY 2 
   (FASTING) 
 
 
57-120 
 
98 
 
19.1 
 
      DAY 3 
   (FASTING) 
 
 
46-122 
 
93.7 
 
20.4 
 
 ON DISCHARGE 
     (FASTING) 
 
 
 
80-116 
 
 
96.2 
 
 
14 
 
0
20
40
60
80
100
120
BLOOD 
SUGAR
ADM DAY 2 DAY 3 DIS
mgs%
BLOOD SUGAR RANGE FOR GROUP III
MEAN
S.D
 
In this category no marked reduction in blood sugar level noted.In the above 
three groups there was a positive correlation between Group I & Group II and 
there  was a negative correlation between Group I & III.
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CLINICAL ASPECTS 
Clinical aspects were analysed under the following headings. 
 
1. Type of myocardial infarction 
2. Killip classification 
3. Complications 
4. Hospital stay 
5. Ejection fraction  
6. outcome  
TYPE OF MYOCARDIAL INFARCTION 
 
 
 
 
GROUP 
 
IWMI 
 
AWMI 
 
ASMI 
 
ALMI 
 
LWMI 
 
PWMI 
 
Group I 
 
  10 
 
     7 
 
     1 
 
     1 
 
     1 
 
    0 
 
Group II 
 
    9 
 
     6 
 
     3 
 
     0 
 
     0 
 
    2 
 
Group III 
 
    2 
 
     6 
 
     1 
 
     0 
 
     1 
 
    0 
 
Out of 50 patients enrolled in the study 21(42%) of patients presented with acute 
IWMI ,19(38%) of patients presented with acute AWMI,5(10%) of patients 
presented with acute ASMI,2(4%) presented with LWMI and 2(4%) presented 
with true PWMI. 
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KILLIP CLASS 
 
        GROUP           I        II        III     IV 
       Group I        12        3         3     2 
       Group II        14        4         2     0 
       Group III         8        2         0     0 
 
                      Most of the patients (68%)  were coming under Killip class I ,  
 
18%  under Killip class II ,10% under Killip class III and  4 % under Killip  
 
class IV.    All patients with acute myocardial infarction were transferred to  
 
intensive  coronary care unit ,where the patients were thrombolysed.9(18%)  
 
were not thrombolysed due to very long median delay after the onset of  
 
symptoms . 
 
 
COMPLICATIONS 
 
 
 
 
 
         GROUP 
 
             LVF 
 
        SHOCK 
     
          VT   
 
        Group I 
   
                3 
    
              0 
    
           1 
 
        Group II 
   
                2 
     
              2 
    
            1 
 
        Group III 
   
                0 
     
              0 
   
            0 
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                                COMPLICATIONS OF MI 
 
 
0
0.5
1
1.5
2
2.5
3
GROUP I GROUP
II
GROUP
III
LVF
SHOCK
VT
 
 
          Out of 50 patients admitted with acute myocardial infarction 5(10%) of 
them developed LVF ,2(4%) of them developed cardiogenic shock, 2(4%)  of 
them developed ventricular tachycardia. 
            After analysing the individual groups ,in  group  I   4(8%) of the patients 
developed complications like LVF,VT &shock. Under group II  5(10%) of the 
patients developed complications . Under group III no complications has been 
observed .There was a significant ( p < 0.05) difference was noticed with 
reference to the complications among the Group I and Group III. There was no 
significant difference among the Group I and Group II patients.  
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HOSPITAL STAY 
 
  
         GROUP                  NUMBER OF DAYS  
         Group I                           6.45 
        Group II                           6.5 
        Group III                            5.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hospital stay in Group I and Group II was prolonged due to development of 
complications. 
5.2
5.4
5.6
5.8
6
6.2
6.4
6.6
DAYS
I II III
GROUP
HOSPITAL STAY
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EJECTION FRACTION 
 
 
     GROUP       RANGE(%)        MEAN(%)    S.D 
     Group I          40-65          52.5    8.7 
     Group II          38-67          53.7    8.4 
     Group III         46-68          57.6    6.4 
 
 
                               EJECTION FRACTION 
                       
                   
0
10
20
30
40
50
60
EJECTION 
FRACTION
I II III
GROUP
MEAN
S.D
 
 
Under group I the mean value of ejection fraction was 52.5% ,under group II the  
mean value of ejection fraction was 53.7% and under group III the mean value of 
EF was 57.6%.On comparing group I and III was a significant (p < 0.05) reduction 
in the ejection fraction.There was no much of difference among group I and 
group II patients. 
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OUTCOME 
 
Outcome was considererd based on their study in the hospital as improved  
 
or expired .the details are furnished in the table given below. 
 
 
          
        GROUP        IMPROVED         DEATH 
        Group I                17              3 
        Group II                17              3 
       Group III                10              0 
 
 
 
 OUTCOME 
 
 
0
2
4
6
8
10
12
14
16
18
PATIENTS
I II III
GROUP
IMPROVED
DEATH
 
 64
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                    
 
 
                          
       DISCUSSION 
 65
DISCUSSION 
 
                Myocardial Infarction continues to have a devastating impact on public 
life as well as personal life savings of an individual and or family.Myocardial 
Infarction places a tremendous burden on the health resources all over the 
world. 
 
AGE 
Age group in this present study ranges as shown below in the  three groups. 
     Age in years  
GROUP Range Mean SD 
 
   TOTAL  
Group 1 42-85 57.7 8.4       20 
Group 2 38-70 57.4 9.6       20 
Group 3 35-60 51.9 8.8       10 
 
A comparison was made with reference to age of the three groups and among 
each other and they were found to be not significant. 
 
GENDER 
 
There are about 39 males and 11 females in this study. The three groups were 
not statistically different from each other with reference to gender.
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RISK FACTOR - HYPERTENSION 
The details with reference to the study group are provided below. 
 
 SYSTOLIC BP mmHg  DIASTOLIC BP mmHg 
GROUP Range Mean SD Range Mean SD 
 
HYPERTENSIVES
Group 1 90-150 124.3 18.43 50-96 79 12            7 
Group 2 80-196 135 35.9 50-120 86.1 20.9            9 
Group 3 100-150 125 16.5 60-96 80.4 11.8            3 
 
There is a negative correlation between blood sugar& hypertension. 
So it is not statistically significant. 
 
CLINICAL ASPECTS 
At the time of admission patients coming under group1 & group 2 presented 
with complications like cardiogenic shock ,arrythmias and left ventricular 
failure.In this study , under group 1 , 3out of 20 patients developed LVF and 1 
out of 20, VT when compared to euglycemic group III patients. 
There was no correlation with the pattern of myocardial infarction and 
hyperglycemia. 
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EJECTION FRACTION 
 
         GROUP         Range      Mean     SD 
        Group I           40-65%       52.5%     8.7 
        Group II           38-67%       53.7%     8.4 
        Group III           46-68%        57.6%     6.4 
 
In this study under group 1 the mean value of ejection fraction was (52.5 ±8.7)% 
and under group III was( 57.6±6.4)%. On comparing group I & III  patients  there 
was a significant (p=0.001) reduction in the ejection fraction. There was not 
much difference among group I & II patients. There is a positive correlation 
between group I  and ejection fraction(admission blood glucose affects the 
ejection fraction). 
 
HOSPITAL STAY 
 
              GROUP                  No.of.Days 
              Group I                      6.45 
              Group II                      6.5 
              Group III                      5.7 
 
 
 68
            In this study some of the group I and group II patients need to stay in the 
hospital for a prolonged period, because these hyperglycemic groups develop 
complications during their hospital stay. But it is not statistically significant. 
 
OUTCOME 
 
Outcome was considered based on their study in the hospital as improved or 
expired. The details are furnished in the table given below. 
           GROUP             IMPROVED                DEATH 
           Group I                     17                     3 
           Group II                     17                     3 
           Group III                      10                     0 
 
 
Mortality was commonly noted in the hyperglycemic groups. 3 deaths were 
commonly noted in group I & II patients due to complications, but it was not 
statistically  significant. 
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CONCLUSION 
 
1. In the previously undiagnosed healthy individuals admitted with acute                 
myocardial infarction 80% of them had elevated blood sugar at the time of 
admission  out of which 40% had stress hyperglycemia and it came down within 
24-48 hours. 
 
2. Elevated admission blood sugar is independent of factors like age ,sex, 
smoking, hypertension, alcoholism and clinical status in this study. 
 
3. Admission blood sugar was elevated to the mean value of 168.6 mg% in non-
diabetic stress hyperglycemic middle-aged and elderly individuals in contrast to 
the non-diabetic euglycemic group. 
 
4. In this study death was significantly higher in diabetic and non-diabetic 
hyperglycemic individuals with acute myocardial infarction  when compared to 
non-diabetic euglycemic group. Thus indicating that the admission blood 
glucose is a predictor of early outcome in acute myocardial infarction. 
 
5. Ejection fraction was significantly reduced(53.1 ±8.55)% in hyperglycemic 
myocardial infarction patients. 
 71
 
 
 
         
         
 
          
         SUMMARY 
 72
SUMMARY 
 
A total of 50 consecutive previously stable active and independent individuals 
free from any drugs or overt illness with established features of acute 
myocardial infarction admitted within 12 hours were evaluated clinically and 
biochemically to find out the prevalence of elevated blood sugar response to 
correlate with hospital outcome as well as selected risk factors. 
 
Blood sugar was elevated in 80% of patients and 40% had stress 
hyperglycemia.Elevated blood sugar was not related to demographic factors 
like age and sex,habits like smoking and alcohol, risk factors like hypertension 
and clinical status like type of myocardial infarction.There is a positive 
correlation between the blood sugar value and the ejection fraction. 
 
Death was noted in both diabetic and non-diabetic hyperglycemic myocardial 
infarction patients. Thus indicating that the admission blood glucose level is a 
predictor of early outcome in acute myocardial infarction. 
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                                              FUTURE PROSPECTIVES 
 
 
 
                           Even though the prognosis in acute MI is greatly affected by the 
elevated blood glucose level, at present there are no related studies regarding 
the intervention  of admission blood glucose level. So it needs further studies 
regarding the management protocol for stress hyperglycemia. 
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   BLOOD SUGAR mgs% S.NO           NAME           IP NO AGE SEX
ADM DAY2 DAY3 DIS 
  DM       BP 
(mm/Hg) 
MI
                                                                                                                                                          GRO
1. Nadarajan 881295 65 m 156 112 100 98 no 126/84 AW
2. Sakuntala 872222 45 f 218 140 106 100 no 140/90 IW
3. Jaithmbivi 860011 55 f 162 110 106 100 no 130/86 AW
4. Cinnathal 879910 70 f 166 98 100 96 no 146/90 IW
5. Selvaraj 885449 56 m 160 112 100 94 no 130/80 IW
6. Gunasekar 880012 52 m 216 114 108 110 no 140/96 AW
7. Venkat 867534 50 m 163 116 114 110 no   90/60 AW
8. Meenatchi 879012 60 f 165 102 102 96 no 110/70 IW
9. Lakshmi 861234 70 f 152 112 104 96 no   90/50 IW
10. Ashok 874567 42 m 166 104 ----- ---- no 120/80 IW
11. Manickam 882125 76 m 184 124 106 104 no 130/84 IW
12. Rajendran 881904 45 m 160 124 110 96 no 134/86 AW
13. Chandran 876389 50 m 158 126 110 100 no 140/90 AW
14. Elangovan 872451 52 m 164 118 114 106 no 150/96 IW
15. Govindaraj 871045 70 m 156 116 104 96 no 140/92 AW
16. David 871035 62 m 160 104 102 100 no 110/70 HL
17. Nagaratnam 860952 67 m 166 116 108 110 no   90/60 AL
18. Vijayan 862311 48 m 166 130 116 108 no 120/80 IW
19. Nathan 881722 56 m 170 120 108 106 no 150/90 AS
20. Prasannan 865232 45 m 164 132 96 98 no 110/70 IW
                                                                                                                                                          GRO
1. Rramayan 860591 45 m 158 192 130 208 yes 100/70 AW
2. Ganapathi 860670 67 m 228 228 184 212 yes 130/80 AW
3. Muniamuthu 862125 64 m 210 163 126 140 yes 126/70 IW
4. Jameel 862367 55 m 217 132 108 170 yes 130/80 IW
5. Kanagammal 864033 70 f 272 110 134 169 yes 130/80 IW
6. Rajagopal 871084 50 m 180 114 136 148 yes 140/96 IW
7. Mohammed 871209 52 m 164 140 180 165 yes 180/120 IW
8. Jayaraman 872795 68 m 210 209 228 180 yes 140/90 IW
9. Ilamaran 872993 60 m 180 108 139 ----- yes   80/60 IW
10. Mangayarkarasi 872583 70 f 200 140 140 184 yes 130/86 PM
11. Kannapillai 873749 70 m 232 286 276 ----- yes   80/50 AW
12. Raja 877244 32 m 154 180 164 160 yes 150/96 AW
13. Rajalakshmi 881552 50 f 180 130 140 136 yes 140/90 AW
14. Kathija bivi 878910 60 f 208 148 160 170 yes 100/60 IW
 80
15. Selvam 881884 50 m 236 240 242 218 yes 160/100 PW
16. Detchinamoorthi 862000 45 m 158 195 180 180 yes 160/110 IW
17. Thumbusami 861493 65 m 180 136 146 136 yes 110/70 AS
18. Gnathammal 861226 70 f 190 146 156 ----- yes 180/100 AS
19. Kumaran 860016 60 m 260 220 210 186 yes 140/90 AS
20. Rajan 869531 45 m 220 136 140 132 yes 130/86 AW
                                                                                                                                                           GRO
1. Manikandan 861506 48 m 124 100 75 98 no 130/86 AW
2. Mathivanan 862097 55 m 123 115 46 80 no 110/70 AW
3. Subramanian 862481 62 m 100 90 98 104 no 150/96 IW
4. Manikandan 863825 61 m 103 80 94 86 no 140/90 IW
5. Palanivel 869847 50 m 84 90 106 98 no 130/80 AW
6. Paneerselvam 869892 48 m 120 110 98 116 no 100/80 AW
7. Suresh 872920 35 m 68 57 96 86 no 110/76 AW
8. Vedaratnam 876094 55 m 79 110 98 76 no 130/80 AW
9. Kaliyaperumal 882080 45 m 119 120 122 116 no 140/96 HL
10. Seethammal 862367 60 f 96 108 104 102 no 110/70 AS
 
 
